Diagnostic Specialty Antibodies Market Report 2026

The diagnostic specialty antibodies market size has grown strongly in recent years. It will grow from $30.96 billion in 2025 to $32.82 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, expansion of hospital-based diagnostic testing, rising adoption of immunoassay techniques, growing awareness of early disease detection, availability of conventional monoclonal antibody technologies.

The diagnostic specialty antibodies market size is expected to see strong growth in the next few years. It will grow to $42.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growth in oncology diagnostics, rising demand for rapid diagnostic tests, expansion of diagnostic laboratories in emerging markets, advancements in recombinant antibody engineering, increasing investments in biomarker-based diagnostics. Major trends in the forecast period include rising adoption of precision diagnostics, expansion of infectious disease testing panels, increasing demand for high-specificity monoclonal antibodies, growth of point-of-care diagnostic assays, standardization of antibody validation and quality control.

The expanding patient pool for HIV diagnosis is anticipated to drive the growth of the diagnostic specialty antibodies market in the coming years. A growing HIV patient pool refers to an increasing number of individuals being diagnosed with human immunodeficiency virus (HIV). As HIV diagnoses rise, demand for diagnostic specialty antibodies increases, creating opportunities for manufacturers to develop and supply antibody-based diagnostic products for HIV testing. These products enable the identification of specific viral biomarkers and support early detection as well as ongoing monitoring of HIV infection. For example, in October 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, HIV testing rates increased by 11% between 2022 and 2023. In 2023, the highest testing rate was reported among gay, bisexual, and other men who have sex with men (GBMSM), at 52,255 per 100,000 people, while testing rates among heterosexual men and heterosexual and bisexual women were significantly lower, at 1,894 and 3,106 per 100,000, respectively. As a result, the growing number of HIV diagnoses is contributing to the expansion of the diagnostic specialty antibodies market.

Major companies operating in the diagnostic specialty antibodies market are concentrating on the development of innovative assays, such as antibody-based assays, to support the diagnosis of rare bleeding disorders and gain a competitive advantage. An antibody assay is a laboratory method used to detect and quantify antibodies present in biological samples. For instance, in May 2023, Versiti, a US-based nonprofit organization, introduced the Anti-von Willebrand Factor (VWF) Antibody Assay. This advanced assay is designed to help clinicians identify patients suspected of having acquired von Willebrand disease (aVWD). Developed through research conducted at the Versiti Blood Research Institute, the assay detects both inhibitory and non-inhibitory antibodies that bind to VWF, providing expanded pathways for anti-VWF antibody detection.

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics company, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher aims to strengthen its diagnostic specialty antibody portfolio by integrating Abcam’s broad range of antibody-based products and scientific expertise, thereby enhancing its capabilities in research applications, diagnostic assays, and specialty antibody development. Abcam plc is a UK-based provider of research and diagnostic antibodies, including monoclonal and polyclonal antibodies, recombinant proteins, related reagents, and custom antibody development and assay support services.

Major companies operating in the diagnostic specialty antibodies market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Agilent Technologies Inc., Sartorius AG, Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Abcam PLC, Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics, Novus Biologicals LLC, Precirix NV, Creative Biolabs Inc., Polymun Scientific Immunbiologische Forschung GmbH, Telix Pharmaceuticals Limited.

North America was the largest region in the diagnostic specialty antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the diagnostic specialty antibodies market report during the forecast period. The regions covered in the diagnostic specialty antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic specialty antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the diagnostic specialty antibodies market by increasing costs for imported raw materials, reagents, and bioprocessing equipment, affecting antibody production and assay development timelines. Supply chain disruptions have particularly impacted monoclonal and recombinant antibody segments, with Asia-Pacific and North America being most affected due to their reliance on cross-border sourcing. Diagnostic laboratories and hospitals face higher procurement costs, slowing test adoption in price-sensitive regions. However, tariffs have encouraged localized manufacturing, regional supplier development, and strategic sourcing diversification, supporting long-term supply chain resilience.

The diagnostic specialty antibodies market research report is one of a series of new reports that provides diagnostic specialty antibodies market statistics, including diagnostic specialty antibodies industry global market size, regional shares, competitors with a diagnostic specialty antibodies market share, detailed diagnostic specialty antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic specialty antibodies industry. This diagnostic specialty antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic specialty antibodies are specifically developed for diagnostic purposes and are used in a wide range of tests to detect and identify particular biomarkers, antigens, or pathogens in patient samples. These antibodies include monoclonal antibodies, which are produced from a single clone of immune cells, and polyclonal antibodies, which are obtained from multiple immune cell lineages.

The main types of diagnostic specialty antibodies include monoclonal antibodies, polyclonal antibodies, and recombinant polyclonal antibodies. Monoclonal antibodies are generated from a single clone of immune cells, resulting in a uniform population of antibodies that bind to a specific antigen. They are used in various applications such as hepatitis, tuberculosis, dengue, oncology, human immunodeficiency virus (HIV), infectious diseases, and others, and are utilized by end users including diagnostic laboratories and hospitals.

The diagnostic specialty antibodies market consists of sales of chimeric antibodies, single-chain antibodies, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.